[go: up one dir, main page]

AR045798A1 - ACID DERIVATIVES 1- (CARBOXIALQUIL) - CICLOPENTILCARBONIL - AMINO- BENZAZEPINA - N- ACETICS REPLACED WITH AMIDOMETILO, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS - Google Patents

ACID DERIVATIVES 1- (CARBOXIALQUIL) - CICLOPENTILCARBONIL - AMINO- BENZAZEPINA - N- ACETICS REPLACED WITH AMIDOMETILO, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS

Info

Publication number
AR045798A1
AR045798A1 ARP040103409A ARP040103409A AR045798A1 AR 045798 A1 AR045798 A1 AR 045798A1 AR P040103409 A ARP040103409 A AR P040103409A AR P040103409 A ARP040103409 A AR P040103409A AR 045798 A1 AR045798 A1 AR 045798A1
Authority
AR
Argentina
Prior art keywords
alkyl
compounds
whose
alkanoyl
amino acid
Prior art date
Application number
ARP040103409A
Other languages
Spanish (es)
Inventor
Dagmar Holtje
Ivan Fischer
Dieter Ziegler
Michael Weske
Katrin Michaelis
Josef Messinger
Axel Pahl
Yasmin Karimi-Nejad
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10344848A external-priority patent/DE10344848A1/en
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of AR045798A1 publication Critical patent/AR045798A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Se describen compuestos con actividad inhibidora de la endopeptidasa neutra (NEP) y/o la endopeptidasa humana soluble (hSEP), así como medicamentos que contienen estos compuestos, en particular medicamentos adecuados para tratamiento o prevención de enfermedades cardiovasculares, disfunción sexual y/o condiciones adversas asociadas con apoptosis. Reivindicación 1: Compuestos de la fórmula general (1), en donde: R1 es hidrógeno o un grupo formador de un éster biolábil; R2 es hidrógeno, alquilo C1-4 o hidroxialquilo C1-4, cuyo grupo hidroxilo está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; y R3 es alquilo C1-4; alcoxi(C1-4)-alquilo(C1-4); hidroxialquilo C1-4, que está sustituido opcionalmente con un segundo grupo hidroxilo y cuyos grupos hidroxilo están esterificados cada uno opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; (alquil C0-4)2amino-alquilo(C1-4); cicloalquilo C3-7; cicloalquil(C3-7)-alquilo(C1-4); fenil-alquilo(C1-4), cuyo grupo fenilo está sustituido opcionalmente 1-2 veces con alquilo C1-4, alcoxi C1-4 y/o halógeno; naftil-alquilo(C1-4); oxoalquilo C3-6; fenilcarbonilmetilo, cuyo grupo fenilo está sustituido opcionalmente 1-2 veces con alquilo C1-4, alcoxi C1-4 y/o halógeno, o 2-oxoazepanilo; o R2 y R3 juntos son alquileno C4-7, cuyos grupos metileno están reemplazados opcionalmente 1-2 veces por carbonilo, nitrógeno, oxígeno y/o azufre, y/o que están sustituidos opcionalmente una sola vez con hidroxi, que está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; alquilo C1-4; hidroxialquilo C1-4, cuyo grupo hidroxilo está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; fenilo o bencilo; y R4 es hidrógeno o un grupo formador de un éster biolábil, y sales fisiológicamente compatibles de los ácidos de fórmula (1) y/o sales de adición de ácido fisiológicamente compatibles de los compuestos de fórmula (1).Compounds with neutral endopeptidase (NEP) and / or soluble human endopeptidase (hSEP) inhibitory activity are described, as well as medications containing these compounds, in particular drugs suitable for treatment or prevention of cardiovascular diseases, sexual dysfunction and / or conditions side effects associated with apoptosis. Claim 1: Compounds of the general formula (1), wherein: R1 is hydrogen or a group forming a bi-volatile ester; R 2 is hydrogen, C 1-4 alkyl or C 1-4 hydroxyalkyl, whose hydroxyl group is optionally esterified with C 2-4 alkanoyl or an amino acid residue; and R3 is C1-4 alkyl; (C1-4) alkoxy-(C1-4) alkyl; C1-4 hydroxyalkyl, which is optionally substituted with a second hydroxyl group and whose hydroxyl groups are each optionally esterified with C2-4 alkanoyl or an amino acid residue; (C0-4 alkyl) 2 amino (C1-4) alkyl; C3-7 cycloalkyl; cycloalkyl (C3-7) -alkyl (C1-4); phenyl (C1-4) alkyl, whose phenyl group is optionally substituted 1-2 times with C1-4 alkyl, C1-4 alkoxy and / or halogen; naphthyl-C1-4 alkyl; C3-6 oxoalkyl; phenylcarbonylmethyl, whose phenyl group is optionally substituted 1-2 times with C1-4 alkyl, C1-4 alkoxy and / or halogen, or 2-oxoazepanyl; or R2 and R3 together are C4-7 alkylene, whose methylene groups are optionally replaced 1-2 times by carbonyl, nitrogen, oxygen and / or sulfur, and / or which are optionally substituted only once with hydroxy, which is optionally esterified with C2-4 alkanoyl or an amino acid residue; C1-4 alkyl; C1-4 hydroxyalkyl, whose hydroxyl group is optionally esterified with C2-4 alkanoyl or an amino acid residue; phenyl or benzyl; and R4 is hydrogen or a biolábil ester forming group, and physiologically compatible salts of the acids of formula (1) and / or physiologically compatible acid addition salts of the compounds of formula (1).

ARP040103409A 2003-09-26 2004-09-22 ACID DERIVATIVES 1- (CARBOXIALQUIL) - CICLOPENTILCARBONIL - AMINO- BENZAZEPINA - N- ACETICS REPLACED WITH AMIDOMETILO, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS AR045798A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10344848A DE10344848A1 (en) 2003-09-26 2003-09-26 New amidomethyl substituted 1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-n-acetic acid derivatives useful to treat cardiovascular disorders or diseases; hypertension; sexual dysfunction; or neurodegenerative disorders
EP04100065 2004-01-12

Publications (1)

Publication Number Publication Date
AR045798A1 true AR045798A1 (en) 2005-11-16

Family

ID=34395054

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103409A AR045798A1 (en) 2003-09-26 2004-09-22 ACID DERIVATIVES 1- (CARBOXIALQUIL) - CICLOPENTILCARBONIL - AMINO- BENZAZEPINA - N- ACETICS REPLACED WITH AMIDOMETILO, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS

Country Status (14)

Country Link
EP (1) EP1670814A1 (en)
JP (1) JP4824562B2 (en)
KR (1) KR101264934B1 (en)
AR (1) AR045798A1 (en)
AU (1) AU2004276002B2 (en)
BR (1) BRPI0414744A (en)
CA (1) CA2539895A1 (en)
IL (1) IL174373A (en)
MX (1) MXPA06003226A (en)
NO (1) NO20061821L (en)
RU (1) RU2368601C2 (en)
SA (1) SA04250283B1 (en)
TW (1) TWI332947B (en)
WO (1) WO2005030795A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1753433A1 (en) * 2004-05-14 2007-02-21 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and pde v inhibitors
MXPA06014448A (en) * 2004-06-23 2007-03-01 Solvay Pharm Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists.
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
ATE464904T1 (en) * 2005-02-18 2010-05-15 Solvay Pharm Gmbh PHARMACEUTICAL COMPOSITIONS CONTAINING NEP INHIBITORS, INHIBITORS OF THE ENDOGENE ENDOTHELIN PRODUCING SYSTEM AND DIURETICS
AU2008287285B2 (en) * 2007-04-13 2013-05-16 Southern Research Institute Anti-angiogenic agents and methods of use
AR071375A1 (en) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh FORMULATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF DEFICIENT PERMEABILITY, PREPARATION AND PRODUCT PROCESS
PL424452A1 (en) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitors of inactive endopeptidase (NEP) and human soluble endopeptidase (hSEP) for prevention and treatment of eye diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI960867A0 (en) * 1993-08-26 1996-02-26 Yamanouchi Pharma Co Ltd Benzazepine derivative, its pharmaceutical mixture and intermediate
DE19502644A1 (en) * 1995-01-28 1996-08-01 Merck Patent Gmbh 4-amino-benzoylguanidine derivatives
DE19510566A1 (en) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepine, benzoxazepine and benzothiazepine N-acetic acid derivatives and process for their preparation and medicaments containing these compounds
DE19750002A1 (en) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonic acid-substituted benzazepinone-N-acetic acid derivatives and processes for their preparation and pharmaceuticals containing these compounds
DE19906310A1 (en) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Use of 3-(1-(2-aralkyl-2-carboxyethyl)-1-cyclopentanecarboxamido)-2,3,4,5-tetrahydro-2-oxo-1H-benz(b)azepine-1-acetic acid derivatives for treating hypertension
CN100591689C (en) * 2002-01-16 2010-02-24 索尔瓦药物有限公司 Solid salts of benzazepine compounds and their use in the preparation of pharmaceutical compounds

Also Published As

Publication number Publication date
KR101264934B1 (en) 2013-05-20
RU2006113946A (en) 2007-11-10
BRPI0414744A (en) 2006-11-21
MXPA06003226A (en) 2006-05-22
HK1096105A1 (en) 2007-05-25
SA04250283B1 (en) 2008-05-26
AU2004276002A1 (en) 2005-04-07
TWI332947B (en) 2010-11-11
CA2539895A1 (en) 2005-04-07
JP2007535482A (en) 2007-12-06
RU2368601C2 (en) 2009-09-27
IL174373A (en) 2011-12-29
EP1670814A1 (en) 2006-06-21
JP4824562B2 (en) 2011-11-30
WO2005030795A1 (en) 2005-04-07
TW200524874A (en) 2005-08-01
IL174373A0 (en) 2006-08-01
AU2004276002B2 (en) 2010-07-22
KR20060101460A (en) 2006-09-25
NO20061821L (en) 2006-06-22

Similar Documents

Publication Publication Date Title
ES2769863T3 (en) 7-hydroxy-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
CO2021010400A2 (en) Benzothiadiazepine compounds and their use as bile acid modulators
ES2327521T3 (en) PROCEDURES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF DISORDERS OF THE PROTEIN AGGREGATION.
JP2020121980A (en) Proteasome inhibitors for treating disorder related to accumulation of non-degraded abnormal protein or cancer
US20220273680A1 (en) Methods of Treating Psychological and Brain Disorders
CO2023016072A2 (en) Benzothia(di)azepine compounds and their use as bile acid modulators
ECSP22040834A (en) BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
CO2022007172A2 (en) Benzothi(di)azepine compounds and their use as bile acid modulators
UY26332A1 (en) NEW DERIVATIVES OF AMINODICARBOXYLIC ACID WITH PHARMACEUTICAL PROPERTIES.
ES2063011T3 (en) ANTIBACTERIAL AGENTS OF QUINOLONAS AND NAFTIRIDINES CONTAINING AN ALPHA-AMINO ACID IN THE SIDE CHAIN OF 7-SUBSTITUTE.
CR20160475A (en) 1-AMINO-2-CYCLLOBUTILETILBORONIC ACID DERIVATIVES
PA8587101A1 (en) NEW DERIVATIVES OF DIHYDROPIRIMIDO [4,5-D] PIRIMIDINONE REPLACED BY AMIINO, MANUFACTURE AND USE OF THE SAME AS PHARMACEUTICAL AGENTS
EP2720693A1 (en) Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders
AR024060A1 (en) NEW PHARMACEUTICALLY ACTIVE COMPOUNDS
ES2182161T3 (en) USE OF PIRIMIDINE DERIVATIVES FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF CANCER.
DOP2006000084A (en) SULFOXIMINO-MACROCICLIC COMPOUNDS AND THEIR SALTS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PREPARATION METHODS AND USES OF THE SAME
CR8411A (en) METHOD FOR TREATMENT OF THE DISEASE ASSOCIATED WITH ADAMTS-5
MX376743B (en) SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS
UY29639A1 (en) AMIDAS REPLACED WITH HETEROARILO UNDERSTANDING AN INSATURED OR CYCLIC LINKER GROUP, AND ITS USE AS PHARMACEUTICAL PRODUCTS
AR045798A1 (en) ACID DERIVATIVES 1- (CARBOXIALQUIL) - CICLOPENTILCARBONIL - AMINO- BENZAZEPINA - N- ACETICS REPLACED WITH AMIDOMETILO, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS
NO20024646D0 (en) Combination therapies with vasculature-damaging activity
US20110183019A1 (en) Methods of screening for and treating autism spectrum disorders and compositions for same
Avraham et al. Beta-Carotene derivatives as novel therapy for the prevention and treatment of autistic symptoms
FR2948940B1 (en) NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2017062924A1 (en) Dosing regimens of pkc activators

Legal Events

Date Code Title Description
FC Refusal